All updates
All updates
today 32监管与产业动态精选评分5858 中文产业新闻精选Chinese source评分6969 晖致 16.5 亿美元收购 Pacira 加码非阿片类疼痛业务
监管与产业动态评分3434 TRex rakes in $117M IPO, while Retension reveals $45M listing - Fierce Biotech
监管与产业动态评分2222 Chutes & Ladders—Vir looks to Liu to lead late-stage push - Fierce Biotech
监管与产业动态评分3030 GSK drinks in Chai Discovery’s AI models after wet-lab validation - Fierce Biotech
监管与产业动态评分2020 Quince relaunches as IRuyla, going all in on lung disease after Hail Mary merger - Fierce Pharma
监管与产业动态评分2525 Ferass Abuzaina named Worldwide President of Surgery at BD - Fierce Biotech
监管与产业动态精选评分5353 GSK commits $800M to R&D, manufacturing hub, as Pennsylvania bonds deepen - Fierce Pharma
中文产业新闻Chinese source评分7070 诺和诺德与 Nanexa 达成 11.65 亿欧元长效多肽递送合作，采用 PharmaShell 平台
中文产业新闻Chinese source评分3131 百年罗氏"慢人一拍"的合作智慧
中文产业新闻Chinese source评分5454 荷兰法院认定默沙东K药皮下注射剂侵犯Halozyme核心专利，多国遭禁售
中文产业新闻Chinese source评分4949 Beam起诉尧唐：指控YOLT-202涉嫌盗用BEAM-302商业秘密
中文产业新闻Chinese source评分6262 晖致以每股36.50美元收购Pacira BioSciences 股权总值16.5亿美元
监管与产业动态评分1717 Quince relaunches as IRulya, going all in on lung disease after Hail Mary merger - Fierce Pharma
中文产业新闻Chinese source评分6464 恒瑞医药每周口服GLP-1 HRS-1596以3亿美元授权诺和诺德海外权益
中文产业新闻Chinese source评分7676 艾博生物与诺华达成mRNA疗法合作 首付款5.75亿美元、总金额约78亿美元
STAT News评分2424 STAT+: Up and down the ladder: The latest comings and goings
BioSpace精选评分5454 TRexBio, Retension raise $161.7M in IPOs; City, Iambic set proposed offering terms
BioSpace精选评分8080 How Abogen went from COVID hype to a $7.8B Novartis deal
BioSpace精选评分6363 Viatris inks $1.65B Pacira buyout to build non-opioid pain therapy business
BioPharma Dive精选评分6161 TRex Bio prices $117M IPO to support immune drug work
中文产业新闻Chinese source评分5858 晖致16.5亿美元现金收购Pacira，加码非阿片类疼痛治疗
中文产业新闻Chinese source评分4141 加码分子胶降解剂！罗氏与迪拓生物达成多靶点开发合作
中文产业新闻Chinese source评分7070 艾博生物与诺华达成ABO2203全球授权，首付5.75亿美元、最高总额77.75亿美元
监管与产业动态精选评分4848 Matchpoint’s $150M tops the week’s private rounds: Venture Report
监管与产业动态评分00 Resources - Fierce Biotech
监管与产业动态精选评分5454 Ono pays $80M for regional rights to trio of Biohaven IgG degraders, including phase 3 Grave’s asset - Fierce Biotech
监管与产业动态评分4343 ‘It’s just survival now’: Why is almost a third of Boston’s life sciences lab space sitting vacant? - Fierce Biotech
监管与产业动态评分2323 Melissa explains it all in menopause team up with Bayer - Fierce Pharma
中文产业新闻Chinese source评分3737 Ultragenyx以2.1亿美元出售优先审评券
中文产业新闻Chinese source评分4040 Ultragenyx 以 2.1 亿美元出售第三张优先审评券，源自 Genglycos 获批
STAT News评分2929 NIH funding uncertainty thwarts U.S. researchers
BioSpace精选评分5858 Merck barred from making subcutaneous Keytruda in 8 European countries
中文产业新闻精选Chinese source评分7272 赛诺菲守擂，诺华豪赌：百亿BD转向自免
中文产业新闻Chinese source评分3434 Caribou Biosciences停止两项异体CAR-T开发并大幅裁员，股价暴跌36%
中文产业新闻Chinese source评分5959 Biohaven以8000万美元首付款将BHV-1300日韩等地区权益授权小野制药
中文产业新闻Chinese source评分6969 Biohub扩大虚拟生物学计划，联合DOE、NIH、Google DeepMind与Meta共投18亿美元建设AI生物学数据底座
中文产业新闻Chinese source评分6161 晖致16.5亿美元收购Pacira BioSciences，获非阿片类疼痛疗法组合
中文产业新闻Chinese source评分6363 16.5亿美元，Viatris收购Pacira BioSciences获两款商业化阶段非阿片类药物
BioPharma Dive精选评分5252 In the hunt for reverse merger targets, Caribou could be prized game